Michael S. Rosol
2019
In 2019, Michael S. Rosol earned a total compensation of $250.1K as Chief Medical Officer at Navidea Biopharmaceuticals, a 2,077% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $35,879 |
|---|---|
| Option Awards | $6,316 |
| Salary | $205,000 |
| Other | $2,915 |
| Total | $250,110 |
Rosol received $205K in salary, accounting for 82% of the total pay in 2019.
Rosol also received $35.9K in non-equity incentive plan, $6.3K in option awards and $2.9K in other compensation.
Rankings
In 2019, Michael S. Rosol's compensation ranked 13,223rd out of 13,971 executives tracked by ExecPay. In other words, Rosol earned more than 5.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 13,223 out of 13,971 | 5th |
Division Manufacturing | 5,383 out of 5,701 | 6th |
Major group Chemicals And Allied Products | 2,103 out of 2,200 | 4th |
Industry group Drugs | 1,804 out of 1,886 | 4th |
Industry In Vitro and In Vivo Diagnostic Substances | 72 out of 77 | 7th |
Source: SEC filing on July 31, 2020.
Rosol's colleagues
We found two more compensation records of executives who worked with Michael S. Rosol at Navidea Biopharmaceuticals in 2019.
News
Navidea Biopharmaceuticals Chief Medical Officer Michael Rosol's 2022 pay slips 8% to $430K
October 5, 2023
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019